CUE.OQ
Latest Trade
7.12USDChange
--(--)Today's Range
-
--52 Week Range
-
9.90As of on the NASDAQ ∙ Minimum 15 minute delay
Previous Close | 7.12 |
|---|---|
Open | -- |
Volume | -- |
3M AVG Volume | 1.68 |
Today's High | -- |
Today's Low | -- |
52 Week High | 9.90 |
52 Week Low | 4.16 |
Shares Out (MIL) | 22.58 |
Market Cap (MIL) | 160.79 |
Forward P/E | -3.63 |
Dividend (Yield %) | -- |
Cue Biopharma Promotes Dr. Anish Suri To President And CSO
Cue Biopharma Announces FDA Acceptance Of Ind For Lead Immuno-Oncology Candidate, Cue-101, In Treatment Of Hpv-Driven Cancers
Cue Biopharma - On April 30,Gary Schuman Resigned As Interim CFO
Cue Biopharma Inc is a development-stage immunotherapy company. The Company is focused at developing biologics engineered to selectively modulate disease-relevant T cell subsets to treat cancer and autoimmune disease. Its Immuno-Oncology pipeline includes CUE-100 Framework, and CUE-200 Framework; and autoimmune pipeline includes MHC Class I Program, and MHC Class II Program. The CUE-100 Framework restricts the activity of T cell populations. The CUE-200 Framework enables potent, long-lived anti-tumor T cell responses. The Autoimmune disease therapy protects the healthy cells from immune attack.
Industry
Biotechnology & Drugs
Executive Leadership
Barry J. Simon
Independent Chairman of the Board
Anish Suri
President, Chief Scientific Officer
Daniel R. Passeri
Chief Executive Officer, Director
Rodolfo J. Chaparro
Executive Vice President - Head of Immunology
Ronald D. Seidel
Executive Vice President - Head of Research and Development
Price To Earnings (TTM) | -- |
|---|---|
Price To Sales (TTM) | 72.93 |
Price To Book (MRQ) | 7.48 |
Price To Cash Flow (TTM) | -- |
Total Debt To Equity (MRQ) | 0.00 |
LT Debt To Equity (MRQ) | 0.00 |
Return on Investment (TTM) | -112.82 |
Return on Equity (TTM) | -94.80 |
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.